Geen onderdeel van een categorie

abbott financial report 2019

Refer to table titled "Non-GAAP Reconciliation of Adjusted Historical Revenue" for a reconciliation of adjusted historical revenue. Abbott Laboratories balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. Established Pharmaceuticals sales increased 7.8 percent on a reported basis in the fourth quarter, including an unfavorable 2.2 percent effect of foreign exchange, and increased 10.0 percent on an organic basis. Sales performance in the quarter was led by strong growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna®, Abbott's market-leading diabetes-specific nutrition brand. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Abbott is issuing first-quarter 2020 guidance for diluted earnings per share from continuing operations under GAAP of $0.40 to $0.42. Sales growth was led by Abbott's market-leading toddler brands, PediaSure® and Pedialyte®. Organic sales growth was led by infectious disease testing in developed markets and cardio-metabolic testing globally, partially offset by lower infectious disease testing sales in Africa. Acquisition-related expenses include costs for legal, accounting, tax, and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for consulting, retention, severance, and the integration of systems, processes and business activities, fair value adjustments to contingent consideration related to a business acquisition, and inventory step-up amortization. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Fundamental company data and analyst estimates provided by FactSet. >50% Next-generation products and services are helping Abbott increase share and generate above-market growth in important treatment areas Shaping Our Future with Life-Changing Technologies ABBOTT Annual report which provides a comprehensive overview of the company for the past year. Specified items include intangible amortization expense, acquisition-related expenses, charges associated with cost reduction initiatives and other expenses. Growth in Structural Heart was led by MitraClip®, Abbott's market-leading device for the minimally invasive treatment of mitral regurgitation, or a leaky mitral heart valve. Sales performance was led by above-market growth in the U.S. and internationally, where Abbott is achieving continued strong adoption of its Alinity family of innovative and highly differentiated diagnostic instruments. See tables titled "Details of Specified Items" for additional details regarding specified items. See tables titled "Details of Specified Items" for additional details regarding specified items. Reported tax rate on a GAAP basis for 2018 includes the impact of an additional $120 million of tax expense for the transition tax associated with the TCJA, as well as the impact of approximately $90 million in excess tax benefits associated with share-based compensation. On an organic basis, sales increased 5.8 percent. Non-GAAP Reconciliation of Adjusted Historical Revenue. A reconciliation of the fourth-quarter tax rates for continuing operations for 2019 and 2018 is shown below: Reported tax rate on a GAAP basis for the fourth quarter of 2018 includes the impact of an additional $85 million of tax expense for the transition tax associated with the TCJA. WHO WE ARE; ABBOTT INDIA LIMITED; BOARD OF DIRECTORS ... accessibility accessibility. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Restructuring and cost reduction initiative expenses include severance, outplacement, asset impairments, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. In Electrophysiology, growth was led by strong performance in cardiac diagnostic and ablation catheters, which are used to help physicians accurately and effectively treat atrial fibrillation, a form of irregular heartbeat. * Total 12M 2019 Abbott sales from continuing operations include Other Sales of $57 million. In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. ABOUT US. "We're entering 2020 with very good momentum and targeting continued strong growth.". Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. See tables titled "Details of Specified Items" for additional details regarding specified items. PDF; Form 10K (HTML) Order Free Hardcopy. Specified items reflect intangible amortization expense of $488 million and other expenses of $226 million, primarily associated with acquisitions, restructuring actions and other expenses, as well as $85 million of additional transition tax related to the TCJA. Specified items reflect intangible amortization expense of $2.178 billion and other expenses of $922 million, primarily associated with acquisitions, restructuring actions and other expenses. Sales performance was led by double-digit organic sales growth in Heart Failure, Electrophysiology, Structural Heart and Diabetes Care. ; Reported diluted EPS from continuing operations under GAAP was $0.59 in the fourth quarter. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. 2018 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.797 billion, or $1.57 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions. Copyright © FactSet Research Systems Inc. All rights reserved. Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal. Inside Abbott Laboratories's 10-K Annual Report: Financial - Expense Highlight. First-quarter worldwide sales of $7.5 billion increased 2.0 percent on a reported basis and 7.1 percent on an organic* basis. ABBOTT LABORATORIES: Releases id now covid-19 interim clinical study results from 1,003 people to provide the facts on clinical performance and to support public health AQ 10/07 Dec 31, 2018. 2018 Tax expense on Earnings from Continuing Operations includes an additional $120 million of tax expense for the transition tax associated with the TCJA, as well as the impact of approximately $90 million in excess tax benefits associated with share-based compensation. See tables titled "Details of Specified Items" for additional details regarding specified items. A reconciliation of the year-to-date tax rates for continuing operations for 2019 and 2018 is shown below: Reported tax rate on a GAAP basis for 2019 includes the impact of a $86 million reduction of the transition tax associated with the TCJA and approximately $100 million in excess tax benefits associated with share-based compensation. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $3.55 to $3.65 for the full year 2020. CONTACT. Filing Group. Medical Devices sales increased 9.7 percent on a reported basis and 11.3 percent on an organic basis in the fourth quarter. During the quarter, Abbott announced the Australian Red Cross Blood Services selected its Alinity-S system for the country's blood and plasma screening. 2019 Annual Report and Form 10K. Data are provided 'as is' for informational purposes only and are not intended for trading purposes.

Onex Westjet Stock Price, Jacob Eason Highlights, Rock Me Gently, Dreams With Teeth Falling Out And Breaking, Eufy Doorbell Rtsp, Virgin Tv On Demand App, AFC East, Canada Immigration Eligibility, Asgard's Wrath - Walkthrough, Demi Moore Ashton Kutcher Mila Kunis, Hallmark Chad Michael Murray, Lil Yachty Real Name, Boyce Avenue - A Thousand Years, Baxter Cardiovascular, Cinderella Glass Slipper Story, Twist And Shout Original Artist, Bird Deterrent, Switzerland Healthcare System, Come Together Aerosmith, Jitterbug Phone Plans Walmart, Eager To Learn New Things, Nhl Jersey History, Jose Calderon Net Worth, Fashion In Spain 2020, David Luiz Wife And Son, Ohshape Editor, Joanne Whalley Val Kilmer, Mikko Lehtonen Nhl 20, Can A French Citizen Work In The Us, The Ranch Season 10, Lucas Pouille Instagram, Angeles Equity Partners, Witcher 3 Xbox Deal, Frank Gore House, Green Dragon Malverde, Gyganic For Fruit And Citrus, Cardi B -- Please Me Music, Luke Treadaway Wife, Dr Br Ambedkar Open University Results 2019, Rigs Mechanized Combat League 2020, Charlie Murphy Funeral, Jon Cryer Demi Moore, False Bay Tvet College Westlake Campus Cape Town, Leonardo Dicaprio Married, The Lab Hoodie, Italian Takeout Near Me, Flinders University Medicine Important Dates, Pichichi Trophy, Offset Definition Engineering,